Answers are grounded in this paper and cite their sources.
By exploiting network medicine and drug repurposing strategies, we previously identified and prioritized clomipramine as one among a subset of suitable non-customary compounds to be tested against amyotrophic lateral sclerosis (ALS). We then investigated the chronic administration of clomipramine in vivo, in the hSOD1-A4V and hSOD1-G85R Drosophila melanogaster ALS models, demonstrating significant efficacy in ameliorating lifespan, improving motor abilities, and mitigating genomic instability and inflammation. The aim of the present work is now to test clomipramine against ALS in the hSOD1-G93A mouse, which remains today among the premier and most exploited and validated preclinical models for studying the disease. Our work demonstrates that the effects of clomipramine are not consistently reproduced across different preclinical models of ALS. In particular, clomipramine emerges as a context-dependent drug in ALS mice. Intraperitoneal administration of clomipramine does not improve overall survival at 10 mg/Kg, but it significantly worsens body weight, motor performance and neuroscore predominantly in male mice. At 20 mg/Kg, clomipramine elicits a clinically meaningful increase in survival time only in the male subgroup, despite a statistically non-significant p-value. Our study reveals the complex profile of clomipramine’s effects, rather than a clear therapeutic action. We trust that further insights and fine tuning through cross-model validation and context-dependent modulation by clomipramine might reveal a novel route for better understanding ALS and exploring clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Armida et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: